IGF-1 DES
guinea pig
The Dose Guy’s verdictAug 28, 20264 sources
No human being has ever taken IGF-1 DES in a clinical study. Not one. The mechanism is real: strip three amino acids off IGF-1 and it dodges the binding proteins that throttle the intact form, making it roughly ten times more potent at driving protein synthesis in muscle cells. People run it for site-specific muscle growth, and the logic is sound. But you are the experiment, the growth signal is not one you can take back, and the safety data is a blank page. If you want systemic IGF-1 with at least some pharmacokinetic data behind it, IGF-1 LR3 is the more documented option.
What it is
IGF-1 DES is a truncated version of IGF-1, the growth factor that sits downstream of everything on the GH axis. Where secretagogues like ipamorelin and CJC-1295 nudge your pituitary to release more of your own growth hormone, and HGH is the hormone itself, IGF-1 DES skips the entire upstream chain and acts on the growth signal directly. The three-amino-acid deletion at the N terminus is the whole trick: it strips the affinity for IGF-binding proteins, the chaperones that normally sequester and slow-release IGF-1 in circulation. Free of those brakes, IGF-1 DES hits the receptor faster, harder, and clears faster.
That profile is why the bodybuilding community uses it as a local tool, injected into a target muscle to push site-specific growth rather than running it systemically. IGF-1 LR3 is the longer-acting sibling people pick for systemic IGF-1 work. IGF-1 DES is the sharp, local instrument with no safety net and no human dosing data behind it.
What the research shows
Zero human trials. The entire evidence base is cell assays and animal work from the late 1980s through 2008:
Realistic protocols
I’m not writing a dosing table for a compound with zero human data and a direct growth-factor mechanism. What the community runs: 50 to 100 mcg injected intramuscularly into the target muscle, pre-workout or immediately post-workout, for a few weeks at a time. The logic is that the short activity window keeps the growth signal local rather than systemic. Bilateral injections for symmetry are standard practice. Some stack it with PEG-MGF post-workout, offsetting the timing so the growth signals arrive in sequence rather than competing. Neither compound has human data alone, so stacking them doubles an unmeasured risk.
If you run it anyway: go low, go short, log everything. Hypoglycemia is a real risk with any IGF-1 compound, so have fast carbs nearby, eat after pinning, and never run it fasted. And understand that the prostate signal from the mouse work is not nothing. A growth factor that causes hyperplasia in every mouse prostate is not one to run open-ended.
Side effects
No human safety data exists. Everything here is mechanism-predicted or community-reported:
